SLC post on antibiotic resistance:
Quote:slcimmuno Member Level Monday, 05/22/17 11:01:36 AM
Re: petemantx post# 182754
Post # of 182846
ABX Resistance would be harder, take longer, given Brilacidin's MOA. Why Bad Bugs have struggled to overcome it -- the body's innate host defense multi-pronged (works in different ways) and thus give less of a means (selective pressure) for bacteria to evolve.
Below another flashback post and a more recent article on HDP-Ms and resistance.
//
Abstract
More than 40 antimicrobial peptides and proteins (AMPs) are expressed in the oral cavity. These AMPs have been organized into 6 functional groups, 1 of which, cationic AMPs, has received extensive attention in recent years for their promise as potential antibiotics. The goal of this review is to describe recent advances in our understanding of the diverse mechanisms of action of cationic AMPs and the bacterial resistance against these peptides. The recently developed peptide GL13K is used as an example to illustrate many of the discussed concepts. Cationic AMPs typically exhibit an amphipathic conformation, which allows increased interaction with negatively charged bacterial membranes. Peptides undergo changes in conformation and aggregation state in the presence of membranes; conversely, lipid conformation and packing can adapt to the presence of peptides. As a consequence, a single peptide can act through several mechanisms depending on the peptide’s structure, the peptide:lipid ratio, and the properties of the lipid membrane. Accumulating evidence shows that in addition to acting at the cell membrane, AMPs may act on the cell wall, inhibit protein folding or enzyme activity, or act intracellularly. Therefore, once a peptide has reached the cell wall, cell membrane, or its internal target, the difference in mechanism of action on gram-negative and gram-positive bacteria may be less pronounced than formerly assumed. While AMPs should not cause widespread resistance due to their preferential attack on the cell membrane, in cases where specific protein targets are involved, the possibility exists for genetic mutations and bacterial resistance. Indeed, the potential clinical use of AMPs has raised the concern that resistance to therapeutic AMPs could be associated with resistance to endogenous host-defense peptides. Current evidence suggests that this is a rare event that can be overcome by subtle structural modifications of an AMP.
Antimicrobial Peptides: Mechanisms of Action and Resistance
B. Bechinger, S.-U. Gorr
First Published November 21, 2016
http://journals.sagepub.com/doi/abs/10.1177/0022034516679973
1
